Arvinas to Showcase Findings from the Vepdegestrant Clinical Development Program at the 2025 ESMO Congress
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Presentation of New Data: Arvinas, Inc. will present new patient-reported outcomes data for vepdegestrant at the ESMO Congress from October 17-21, 2025, focusing on its use in treating ER+/HER2- advanced breast cancer with ESR1 mutations.
Vepdegestrant Overview: Vepdegestrant is an investigational PROTAC estrogen receptor degrader being developed as a potential monotherapy and in combination therapies for advanced breast cancer, with FDA acceptance of its New Drug Application and Fast Track designation.
Collaboration with Pfizer: Arvinas has a global collaboration with Pfizer for the co-development of vepdegestrant, and they plan to select a third party for its out-licensing and commercialization.
Forward-Looking Statements: The press release includes forward-looking statements regarding the potential clinical benefits and commercialization of vepdegestrant, highlighting various risks and uncertainties that could affect these outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Revenue Rebound Potential is Significant
- Revenue Decline: Pfizer projects its 2025 revenue to be between $61 billion and $64 billion, significantly lower than the record-breaking over $100 billion in 2022, indicating challenges in revenue recovery post-COVID-19.
- Shift in Drug Development Focus: The company has struggled to prioritize other drug developments after the success of its COVID-19 vaccine, leading to slow progress in its drug pipeline and impacting overall market competitiveness.
- New Drug Market Potential: Pfizer aims to launch several new billion-dollar oncology drugs by 2030 and has entered a weight-loss drug market through its $10 billion acquisition of Metsera, which could be worth over $150 billion annually, showcasing significant future growth potential.
- Acquisitions Create New Opportunities: The acquisitions of Arena Pharmaceuticals in 2022 and Seagen for $43 billion in 2023 inject new prospects into Pfizer's pipeline, although these new drugs will not complete testing until after 2030, providing hope for future growth despite current challenges.
Continue Reading
U.S. Stock Market Eyes Upcoming Earnings Reports
- Earnings Outlook: Next week, earnings reports from tech giants Alphabet and Amazon are highly anticipated, especially after Microsoft's report led to a 10% stock drop despite beating expectations, indicating a shift in investor scrutiny towards profitability and growth metrics.
- Job Cuts and Efficiency: Amazon announced a restructuring that will eliminate 16,000 jobs, adding to the 14,000 cuts made in October, resulting in a 10% reduction in its corporate and tech workforce, with CEO Andy Jassy emphasizing that AI-driven efficiency gains will significantly impact operational costs moving forward.
- Labor Market Insights: A crucial jobs report is set to be released next Friday, alongside the Job Openings and Labor Turnover Survey (JOLTS), providing investors with insights into the labor market, particularly after the Fed indicated an improving economic outlook, which may alter interest rate expectations.
- Government Shutdown Risks: The market is also wary of a potential partial government shutdown, as a planned Senate vote on funding has stalled, despite a strong January performance; this uncertainty could lead to increased volatility, prompting investors to remain cautious in their strategies.
Continue Reading